Kelly Renee Gwartney, MA PLMHP Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1903 4th Corso, Nebraska, NE 68410 Phone: 402-873-5505 Fax: 402-873-6374 |
News Archive
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
Smoking killed almost 5 million people around the world in 2000, reveals research in Tobacco Control. Over half the deaths were in smokers aged 30 to 69.
Older people with higher amounts of a key protein in their brains also had slower decline in their memory and thinking abilities than people with lower amounts of protein from the gene called brain-derived neurotrophic factor, or BDNF, according to a study published in the January 27, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology.
Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today that it has been informed that percutaneous tibial nerve stimulation (PTNS), the procedure performed using the Uroplasty Urgent PC Neuromodulation System, will receive a category 1 CPT reimbursement code. This is expected to occur when those codes are published by the Centers for Medicare and Medicaid Services, which is expected in October 2010.
› Verified 9 days ago